Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer.

CONCLUSION: Lapatinib exposure can be safely and significantly increased through intermittent dosing but reaches a ceiling that currently impedes clinical translation of the treatment hypothesis. Preliminary efficacy data suggest that exposures approaching those seen in mouse models can result in highly significant tumor responses.
PMID: 24711549 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - April 7, 2014 Category: Cancer & Oncology Authors: Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM Tags: J Clin Oncol Source Type: research